GBA1 and Gaucher disease: This fits with the hypothesis that E326K reduces glucosylceramidase activity sufficiently to induce alpha-synuclein, but not glucosylceramide, accumulation, thus explaining its association with Parkinson’s disease but not Gaucher disease (Duran et al., 2013).